AI-generated summary
Artificial intelligence (AI), machine learning, and molecular modulation techniques are revolutionizing antibiotic research by accelerating the discovery and development of new antimicrobial drugs. The rising threat of antimicrobial resistance—where bacteria survive existing drugs through mutations—has made the search for novel antibiotics urgent. AI-based methods can rapidly analyze vast chemical datasets, identifying promising molecules far more efficiently than traditional screening processes. For example, AI algorithms have recently discovered new compounds like abaucin and halicin, which show effectiveness against resistant bacteria such as Acinetobacter baumannii, a dangerous pathogen recognized by the World Health Organization.
AI leverages machine learning, deep learning, and reinforcement learning to predict molecules’ antibacterial potential by recognizing complex patterns in large datasets. This enables faster, more cost-effective, and targeted antibiotic development, reducing drug discovery time by years and cutting costs significantly. Furthermore, AI can predict potential toxic effects early on, improving safety profiles and guiding researchers toward the most promising candidates. Although AI transforms pharmacology by automating data processing and preliminary analysis, human creativity and expertise remain crucial for validating AI-generated results and conducting exploratory research. Thus, AI acts as a powerful tool that complements human talent, enhancing the speed and precision of new antibiotic development in the fight against resistant pathogens.
Artificial intelligence, machine learning, and molecular modulation techniques are accelerating research for the development of new antibiotics. Artificial intelligence is accelerating the future in different areas. Modern medicine has reaped great benefits from the use of antimicrobial drugs to treat infectious diseases caused by bacteria. However, the recurrent use of these drugs in humans, animals, […]
Artificial intelligence, machine learning, and molecular modulation techniques are accelerating research for the development of new antibiotics.
Artificial intelligence is accelerating the future in different areas. Modern medicine has reaped great benefits from the use of antimicrobial drugs to treat infectious diseases caused by bacteria. However, the recurrent use of these drugs in humans, animals, and the environment has contributed to the emergence of the phenomenon of antimicrobial resistance, which has soon become one of the greatest threats to public and environmental health.
Antimicrobial resistance causes certain microorganisms to survive available drugs, by acquiring mutations that allow them to limit the absorption of a drug or inactivate it. Many microorganisms also develop multiresistance, surviving the use of different classes of antibiotics. Therefore, the development of new antimicrobial strategies is increasingly necessary.
Among the main causes, without a doubt, is the incorrect use of antibiotics, which are often taken for diseases of viral origin, such as flu or cold, for which they are not indicated, in addition to poor adherence to therapies. Today, the Artificial intelligence and machine learning are paving the way for the development of new molecules that could solve the problem.
A study published in Nature Chemical Biology has demonstrated the effectiveness of artificial intelligence in identifying new antibiotics and in the fight against antimicrobial resistance. The researchers used machine learning to analyze, almost in real time, more than 7,500 molecules and their effect against the superbug Acinetobacter baumannii, considered by the World Health Organization (WHO) as one of the most dangerous bacteria in the world due to its resistance to antibiotics.
In just two hours, the AI algorithm discovered a new compound, called abaucin, that was shown to inhibit the growth of A. baumannii. Subsequent tests confirmed the targeted activity of this molecule against the gram-negative pathogen. Abaucine therefore represents a promising candidate for developing new antibiotics against bacteria that have developed antibiotic resistance.
The discovery of abaucin by artificial intelligence is not an isolated case. A few years ago, a team of researchers at the Massachusetts Institute of Technology (MIT) used machine learning to analyze more than 2,500 compounds, identifying a new antibiotic called halicin, which demonstrated activity against several pathogens resistant to traditional drugs. Researchers at the University of Oxford are also using artificial intelligence techniques to accelerate the discovery of new antibiotics by analyzing large chemical datasets.
Given the enormous potential of this technology, several pharmaceutical companies have already created research centers dedicated to artificial intelligence, to reduce the time and costs of developing new drugs, adopting machine learning, deep learning and predictive analysis techniques in the various phases of the research, development and experimentation process.
How artificial intelligence works for the discovery of new molecules
AI uses machine learning algorithms to quickly sift through huge databases of chemical compounds. Taking advantage of the potential of artificial neural networks, which simulate the functioning of human neurons, and deep learning, based on multi-layered artificial neural networks capable of learning autonomously from data, AI systems are trained to recognize patterns in big data with which to predict which molecules are most likely to have antibacterial activity.
A reinforcement learning technique is then applied, whereby the algorithm learns through trial and error by interacting with the environment. In this way, AI can test virtually millions of compounds in a very short time and identify the most promising ones to develop and test in the laboratory.
Traditionally, the process of discovering new antibiotics requires lengthy and expensive chemical screenings , which involve the synthesis and evaluation of a large number of compounds. But thanks to AI, it is now possible to significantly accelerate this process. Machine learning algorithms can analyze large amounts of scientific data, such as structural information about bacteria, data from chemical screenings , and information about bacterial resistance mechanisms, to identify potential antibiotic candidates.
In addition, AI can improve accuracy in the selection of antibacterial compounds. Through machine learning, in fact, it is possible to analyze the interactions between chemical compounds and bacterial targets to design antibiotics that are more effective in attacking specific resistance mechanisms. This approach allows the development of targeted drugs, which act selectively on pathogenic bacteria, minimizing side effects for the beneficial microorganisms present in the body.
In essence, thanks to AI, the process of discovering and developing new drugs can be considerably faster, more efficient, and more economical. An Accenture
As highlighted in the Bankinter Innovation Foundation’s Megatrends 2024 , artificial intelligence and deep learning are revolutionizing pharmacology, influencing all phases of the process, from design to property forecasting. However, it should be clarified that the use of artificial intelligence in medicine does not have the ultimate goal of replacing human talent, but rather offering a support tool to free oneself from automatic tasks.
In this way, researchers can spend more time on creative and exploratory research activities, leaving aside repetitive ones. Human intuitions and inventiveness remain essential in the process of discovering new drugs and therapies and will be so in the future as well. In addition, human intervention remains indispensable for the validation of the results obtained by AI, an essential step to ensure the reliability and validity of the tests.
